News

The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

Elaine Ye Wang, MD, discusses adapting transscleral laser therapy (TLT) using MicroPulse technology into her practice and the benefits of using the technique.

According to researchers, lesions in women’s eyes were significantly more likely to occur in the central retina compared with those in men’s eyes.

The ophthalmic solution from VivaVision is being studied for the treatment of glaucoma.

An inexpensive laser could increase access to OCT imaging, helping to catch eye problems early.

Doheny Eye Institute announced Ghosh was recognized by Research to Prevent Blindness and the International Retinal Research Foundation.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.

The event is a forum for the exchange of ideas between leading scientists in diverse fields to bring their knowledge to the challenges of glaucoma and help set the course for future glaucoma research.

Surgeons from iLink Centers of Excellence offer pearls, from optimal scheduling to networking.

The organization aims to educate patients and doctors on one of the leading causes of blindness worldwide.

According to the company, topline results from the clinical trial are expected by the third quarter of 2024.

According to the company, the Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH, with interim efficacy data anticipated by the end of the year.

Treatment option offers positive outcome for patients diagnosed with disease.

According to the company, CTx-PDE6b in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.

Therapeutic has fewer adverse effects in patients with POAG, OHT.

According to company officials,the new image modality provides additional retinal visualization to our customers as they manage their patient’s treatment and ongoing care.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

According to the company, the Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.

The photochromic lenses, available in Singapore, provide added protection against intensive sunlight and can darken outdoors and fade back to transparent indoors.

New option a potential treatment for patients diagnosed with dry eye disease.

In a Wilmer Eye Institute study, in mice and human cell models, the drug 32-134D lowered protein levels known to contribute to diabetic macular edema and diabetic retinopathy

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.